Volume 5, Number 9, Supplement 4 (October 2007)

Contents

3

Pathobiology of Oral Mucositis: Novel Insights and Opportunities
Stephen T. Sonis, DMD, DMSc

Harvard Medical School, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute, Boston, Massachusetts

abstract

full text

3.77 Mb

13

Clinical and Economic Consequences of Mucositis Induced by Chemotherapy and/or Radiation Therapy
Barbara A. Murphy, MD

Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee

abstract

full text

248 kb

23

Consequences of Mucositis-Induced Treatment Breaks and Dose Reductions on Head and Neck Cancer Treatment Outcomes
David I. Rosenthal, MD

The University of Texas M. D. Anderson Cancer Center, Houston

abstract

full text

229 kb

33

Novel Agents for the Treatment of Mucositis
Marshall R. Posner, MD, and Robert I. Haddad, MD

Harvard Medical School and Dana-Farber Cancer Institute, Boston, Massachusetts

abstract

full text

174 kb

Financial disclosures: Dr. Sonis has served as a consultant for Amgen, Inc. and MedImmune, Inc. and has served as a consultant for Biomodels and Affiliates. Dr. Murphy has received research support from MedImmune, Inc.; has served on the speaker’s bureau for Amgen, Inc. and Bristol-Myers Squibb Company; and has served as a consultant for Bristol-Myers Squibb Company and MedImmune, Inc. Dr. Rosenthal has received honoraria from MedImmune, Inc. and has served as a consultant for Amgen, Inc. and Imclone. Dr. Posner has received honoraria from Amgen, Inc., Bristol-Myers Squibb Company, Sanofi-Aventis; has received clinical research support from MedImmune, Inc., Genentech, Inc., Sanofi-Aventis, AstraZeneca, Bristol Myers Squibb Company, OSI Pharmaceuticals, Inc., Amgen, Inc., the National Cancer Institute, National Institute of Allergy and Infectious Diseases, Viventia Biotech Inc., and Millennium Pharmaceuticals, Inc.; and has served as a consultant for Amgen, Inc., Millenix, GlaxoSmithKline plc., the National Cancer Institute, BioVex, Idera Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Sanofi-Aventis, Polaris Pharmaceuticals, Inc., Allos Therapeutics, Inc., Boehringer Ingelheim GmbH, Oxigene, Imclone, PharmArray, and Premedior. Dr. Haddad has received research support from MedImmune, Inc.

This supplement is supported by an unrestricted educational grant provided by Amgen, Inc.

© 2007 Elsevier Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without written permission from the publisher.

The opinions expressed herein are those of the authors or advertisers. The authors, editors, and publishers make every effort to ensure that no inaccurate or misleading data, opinion, or statement is published in this journal and that drug names, dosages, and recommendations are accurate. However, readers should confirm all dosage schedules against the manufacturer’s package information data. The Publisher, Editorial Board, and their employees accept no liability whatsoever for the consequences of any inaccurate or misleading data, opinion, or statement.